The article by Schuller and Govaerts,1 has major differences compared with our study2 regarding the patients treated, mode of treatment, dosage of drug used, and duration of treatment.Schuller and Govaerts1 have treated patients with chronic progressive multiple sclerosis (MS), and their main results are related to the disability of the patients. We have treated pa
Achiron A, Pras E, Gilad R, et al. Treatment of Multiple Sclerosis With Intravenous Immunoglobulins-Reply. Arch Neurol. 1994;51(3):234. doi:10.1001/archneur.1994.00540150020007
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: